Skip to main content

Table 2 Clinicopathological characteristics according to CIP2A expression a

From: Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells

Characteristic Moderate to low CIP2A expression, High CIP2A expression, P-value
n = 103 (%) n = 20 (%)
Median age (IQR) 55 (49.0 to 67.0) 49 (40.75 to 55.50) 0.401
Advanced clinical stage (stages III and IV) 23 (22.3) 11 (55.0) 0.011
Microvascular invasion 23 (22.3) 9 (45.0) 0.001
HER2-positiveb 47 (45.6) 6 (30.0) 0.337
High p-Akt expression 49 (47.6) 12 (60.0) 0.338
5-year PFSc 76.7% 55% 0.034
  1. aCIP2A, Cancerous inhibitor of protein phosphatase 2A; HER2, Human epidermal growth factor receptor 2; PFS, Progression-free survival. bHER2-positive was defined as an immunohistochemical staining score of 3+ or 2+ with gene amplification shown by fluorescence in situ hybridization. cMedian follow-up period 50.5 months (IQR = 34.1 to 86.8).